临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Terbinafine
中文名称: 特比萘芬
CAS号:91161-71-6
分子式: C21H25N 分子量: 291.43
产品形式: Free Base
研发状态: Recruiting
研发用途: Chronic Hepatitis b
研究机构: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
研发日期: April 13 2022
研发阶段: Phase 1 : Phase 2
Terbinafine (SF 86-327,TDT 067) is used to treat infections caused by a fungus. It works by killing the fungus or preventing its growth.
Belumosudil (KD025)
中文名称:2-[3-[4-[(1H-吲唑-5-基)氨基]喹唑啉-2-基]苯氧基]-N-异丙基乙酰胺
CAS号:911417-87-3
分子式: C26H24N6O2 分子量: 452.51
产品形式: free base
研发状态: Terminated
研发用途: System; Sclerosis; Diffuse Cutaneous Systemic Sclerosis
研究机构: Kadmon a Sanofi Company; Sanofi
研发日期: June 26 2019
研发阶段: Phase 2
Belumosudil (KD025, SLx-2119) is an orally available, and selective ROCK2 inhibitor with IC50 and Ki of 60 nM and 41 nM, respectively. Phase 2.
Rabusertib (LY2603618)
中文名称: N-[5-溴-4-甲基-2-[(2S)-2-吗啉甲氧基]苯基]-N'-(5-甲基-2-吡嗪基)脲
CAS号:911222-45-2
分子式: C18H22BrN5O3 分子量: 436.30
产品形式: free base
研发状态: Completed
研发用途: Solid Tumors
研究机构: Eli Lilly and Company
研发日期: May-11
研发阶段: Phase 1
Rabusertib (LY2603618, IC-83) is a highly selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated. Rabusertib (LY2603618) induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Rabusertib (LY2603618) induces bak-dependent apoptosis in AML cell lines.
Domatinostat (4SC-202)
中文名称:(2E)-N-(2-氨基苯基)-3-[1-[[4-(1-甲基-1H-吡唑-4-基)苯基]磺酰基]-1H-吡咯-3-基]-2-丙烯酰胺
CAS号:910462-43-0
分子式: C23H21N5O3S 分子量: 447.51
产品形式: free base
研发状态: Completed
研发用途: Advanced Hematologic Malignancies
研究机构: 4SC AG
研发日期: Mar-11
研发阶段: Phase 1
Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
PF-04929113 (SNX-5422)
CAS号:908115-27-5
分子式: C25H30F3N5O4 分子量: 521.53
产品形式: free base
研发状态: Terminated
研发用途: Cancer
研究机构: Esanex Inc.
研发日期: February 7 2017
研发阶段: Phase 1
PF-04929113 (SNX-5422) is a potent and selective HSP90 inhibitor with Kd of 41 nM and induces Her-2 degradation with IC50 of 37 nM. Phase 1/2.
Sodium Hyaluronate
中文名称:透明质酸钠
CAS号:9067-32-7
分子式: C14H20NNaO11R 分子量: 401.30
产品形式: free base
研发状态: Completed
研发用途: Parkinson Disease
研究机构: IRCCS San Raffaele Roma
研发日期: February 2 2016
研发阶段: Phase 2
Sodium hyaluronate is the sodium salt of hyaluronic acid, a glycosaminoglycan found in various connective tissue of humans.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
